Archive

Neovasc Reducer™ Featured In FOCUS Magazine

NASDAQ, TSX: NVCN VANCOUVER, CA, and BERLIN, DE, November 26, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...

Read More

Neovasc Reducer™ Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola

  - Educational events featuring the Reducer hosted in Germany and Italy -   VANCOUVER, CA, COBURG, DE, and COTIGNOLA, IT, November 22, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and...

Read More

Neovasc Tiara™ Progress Highlighted at PCR London Valves 2019

 NASDAQ, TSX: NVCN   VANCOUVER, November 19, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that...

Read More

Neovasc Appoints Cardiovascular Industry Veteran Bill Little as Chief Operating Officer

®NASDAQ, TSX: NVCN Vancouver, BC, Nov. 06, 2019  -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the appointment of...

Read More

Neovasc Announces Third Quarter 2019 Financial Results

NASDAQ, TSX: NVCN Recent Highlights  Delivered continued revenue growth for Neovasc ReducerTM (“Reducer”) Reducer added to the European Society of Cardiology Practice Guidelines for the treatment of refractory angina Reducer featured at the 40th Annual National Congress of the Italian Society of Interventional Cardiology Announced Norman...

Read More

Neovasc to Participate in Stifel 2019 Healthcare Conference and Cannacord Genuity 13th Annual MedTech & Diagnostics Forum

®NASDAQ, TSX: NVCN Vancouver, BC, Nov. 06, 2019  -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that Fred...

Read More

Neovasc to Provide Update on TF/TS Tiara Program at PCR Valves 2019

®NASDAQ, TSX: NVCN Vancouver, BC, Nov. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More